コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ths after a subtotal excision of a brainstem pilocytic astrocytoma.
2 considered responsible for tumorigenesis of pilocytic astrocytoma.
3 multiforme (GBM) to the indolent, low-grade pilocytic astrocytoma.
4 - predominantly low-grade glial tumours like pilocytic astrocytoma.
5 craniopharyngioma, ependymoma, and juvenile pilocytic astrocytoma.
6 its central importance to the development of pilocytic astrocytomas.
7 s system tumors, including neurofibromas and pilocytic astrocytomas.
8 ignature that distinguished between GBMs and pilocytic astrocytomas.
9 pects of NF1 gene expression in six sporadic pilocytic astrocytomas.
10 e region on chromosome 17q occur in sporadic pilocytic astrocytomas.
13 e discrete cluster of gliomas identified the pilocytic astrocytomas, a second grouped the 1p/19q code
15 on a 4-yr-old male with a diagnosis of acute pilocytic astrocytoma and global cerebral hypoxic ischem
16 nses were observed (one in thalamic juvenile pilocytic astrocytoma and one in optic pathway glioma) a
17 iffuse glioma showed molecular similarity to pilocytic astrocytoma and relatively favorable survival.
18 o differentiate medulloblastoma cancers from pilocytic astrocytoma and two molecular subtypes of epen
19 a tumours (including 55 Medulloblastomas, 36 Pilocytic Astrocytomas and 26 Ependymomas) were scanned
20 er, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, and non-small-cell lung cancer (e
21 of seven oligodendrogliomas, three of three pilocytic astrocytomas, and one of five glioblastoma mul
22 NF1 gene acts as a tumor suppressor gene in pilocytic astrocytomas, and that NF1 gene expression wou
24 a case of a patient diagnosed with a grade 1 pilocytic astrocytoma at the age of 2 years, approximate
26 ave measurable non-enhancing disease (except pilocytic astrocytoma) at baseline using the Response As
28 n with high fetal growth appeared to involve pilocytic astrocytomas, but not other astrocytomas, medu
30 presents tumors with molecular similarity to pilocytic astrocytomas, class II tumors are similar to 1
31 ive in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations
32 tratum 1 comprised patients with WHO grade I pilocytic astrocytoma harbouring either one of the two m
33 ole of the NF1 gene as a tumor suppressor in pilocytic astrocytomas, however, remains to be proven.
34 viously, TDP-43 was detected in RFs of human pilocytic astrocytomas; however, involvement of TDP-43 i
35 were most frequent in supratentorial midline pilocytic astrocytomas, in patients with progressive/rec
36 increased risk of brain tumors (particularly pilocytic astrocytomas) independently of gestational age
39 tween the ADC metrics and cellularity of the pilocytic astrocytomas, medulloblastomas, and ependymoma
40 endymal giant cell astrocytomas (n = 4) or a pilocytic astrocytoma (n = 1) were treated with oral rap
42 rs including oligodendroglioma, astrocytoma, pilocytic astrocytoma, oligoastrocytoma, anaplastic astr
44 e two major genomic alterations in pediatric pilocytic astrocytoma (PA) are NF1 loss and KIAA1549:BRA
49 medulloblastoma (MB), which is malignant, to pilocytic astrocytoma (PA), a primarily benign tumor, an
50 ignated MG-Act in BRAF-fused, MAPK-activated pilocytic astrocytoma (PA), but not in high-grade glioma
52 of the most common brain tumor in children (pilocytic astrocytoma [PA]), we identify glutamatergic p
58 cells, and PFA/PFB ependymoma and cerebellar pilocytic astrocytoma resemble the prenatal gliogenic pr
61 5 astrocytic tumors including 21 GBMs and 19 pilocytic astrocytomas using oligonucleotide-based micro